Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma

Liver International

Volumn 30, Issue 7, 2010, Pages 1027-1032

  Iwadou, Shouta ^a   Nouso, Kazuhiro ^b   Kuwaki, Kenji ^b   Kobayashi, Yoshiyuki ^b   Nakamura, Shinichiro ^b   Tanaka, Hironori ^c   Miyoshi, Kenji ^b   Ohnishi, Hideki ^b   Miyake, Yasuhiro ^b   Shiraha, Hidenori ^b   Iwasaki, Yoshiaki ^b   Shiratori, Yasushi ^d   Yamamoto, Kazuhide ^b  

^a HIROSHIMA CITY HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Miyamoto Hospital   (Japan)

Author keywords

Hepatocellular carcinoma; Recurrence; Time dependent analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; VITAMIN K GROUP; WARFARIN; AFP PROTEIN, HUMAN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ASSESSMENT; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROWAVE COAGULATION THERAPY; MICROWAVE THERAPY; PROGNOSIS; RADIOFREQUENCY ABLATION; RISK FACTOR; TUMOR VOLUME; BLOOD; CARCINOMA, HEPATOCELLULAR; JAPAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PROTHROMBIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; KAPLAN-MEIER ESTIMATE;

EID: 77957110435     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02252.x     Document Type: Article

References (37)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-17.
2. Colombo M, De Franchis R, Del Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-80.
3. Tsukuma H, Hiyama T, Tanaka S. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328:1797-801.
4. Williams R, Melia WM, Johnson PJ. Serum alpha-foetoprotein in hepatocellular carcinoma - value in diagnosis, and prognosis. Ann Acad Med Singapore 1980, 9:245-50.
5. Koike Y, Shiratori Y, Sato S. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000, 32:1216-23.
6. Arii S, Tanaka J, Yamazoe Y. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992, 69:913-9.
7. Izumi R, Shimizu K, Ii T. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994, 106:720-7.
8. Ko S, Nakajima Y, Kanehiro H. Influence of associated viral hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. World J Surg 1996, 20:1082-6.
9. Shirabe K, Takenaka K, Taketomi A. Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996, 77:1050-5.
10. Makuuchi M, Kokudo N, Arii S. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008, 38:37-51.
11. Brown JE, Cook RJ, Major P. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
12. Preston DM, Bauer JJ, Connelly RR. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. Urology 1999, 53:131-8.
13. Fisher B, Anderson S, Fisher ER. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991, 338:327-31.
14. Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981, 37:67-78.
15. Nouso K, Matsumoto E, Kobayashi Y. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol 2008, 23:453-8.
16. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 2006, 12:828-9.
17. Okuda K, Ohtsuki T, Obata H. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-28.
18. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998, 28:751-5.
19. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-38.
20. Kudo M, Chung H, Haji S. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004, 40:1396-405.
21. Tateishi R, Yoshida H, Shiina S. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005, 54:419-25.
22. Jorgensen B, Fischer E, Ingeberg S. Decreased blood platelet volume and count in patients with liver disease. Scand J Gastroenterol 1984, 19:492-6.
23. Pohl A, Behling C, Oliver D. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96:3142-6.
24. Tarao K, Takemiya S, Tamai S. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997, 79:688-94.
25. Peng YC, Chan CS, Chen GH. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology 1999, 46:3208-11.
26. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986, 6:133-7.
27. Bellet DH, Wands JR, Isselbacher KJ, Bohuon C. Serum alpha-fetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci USA 1984, 81:3869-73.
28. Ikeda K, Saitoh S, Tsubota A. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993, 71:19-25.
29. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19:61-6.
30. Aoyagi Y, Oguro M, Yanagi M. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996, 77:1781-6.
31. Ikeda K, Saitoh S, Arase Y. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999, 29:1124-30.
32. Fujiyama S, Tanaka M, Maeda S. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002, 62((Suppl. 1)):57-63.
33. Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. Liver Int 2009, 29:443-8.
34. Hosaka T, Ikeda K, Kobayashi M. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int 2009, 29:736-42.
35. Tarao K, Rino Y, Takemiya S. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma. Intervirology 2000, 43:20-6.
36. Chen LS, Yen MF, Wu HM. Predictive survival model with time-dependent prognostic factors: development of computer-aided SAS Macro program. J Eval Clin Pract 2005, 11:181-93.
37. Liao CS, Yang KC, Yen MF, Hsiu-Hsi Chen T. Time-varying predictors for clinical surveillance of small hepatocellular carcinoma. Cancer J 2005, 11:226-33.